SAM
BHVN

Shell Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Shell Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,862
Closed -$281K – 1433
2022
Q3 		$281K Sell
1,862
-486
-21% -$72K 0.01% 862
2022
Q2 		$342K Buy
2,348
+4
+0.2% +$511 0.01% 918
2022
Q1 		$278K Sell
2,344
-346
-13% -$43.2K 0.01% 1065
2021
Q4 		$371K Buy
2,690
+19
+0.7% +$2.42K 0.01% 1026
2021
Q3 		$371K Sell
2,671
-110
-4% -$13.7K 0.01% 996
2021
Q2 		$270K Buy
2,781
+150
+6% +$12.2K 0.01% 1149
2021
Q1 		$180K Sell
2,631
-1,992
-43% -$161K ﹤0.01% 1173
2020
Q4 		$396K Hold
4,623
– – 0.01% 895
2020
Q3 		$301K Hold
4,623
– – 0.01% 904
2020
Q2 		$338K Sell
4,623
-83
-2% -$4.42K 0.01% 836
2020
Q1 		$160K Sell
4,706
-71
-1% -$3.25K ﹤0.01% 1057
2019
Q4 		$260K Sell
4,777
-134
-3% -$6.63K 0.01% 1081
2019
Q3 		$205K Sell
4,911
-42
-0.8% -$1.77K ﹤0.01% 1129
2019
Q2 		$217K Sell
4,953
-112
-2% -$6.31K ﹤0.01% 1115
2019
Q1 		$261K Hold
5,065
– – 0.01% 1063
2018
Q4 		$187K Sell
5,065
-400
-7% -$14.4K ﹤0.01% 1046
2018
Q3 		$205K Buy
+5,465
New +$201K ﹤0.01% 1099

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Shell Asset Management's BHVN Position: Q4 2022 in Review

Shell Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,862 shares — an estimated $281K sold.

Shell Asset Management first reported a position in BHVN in Q3 2018 and held it in 17 quarters. The position peaked at $396K in Q4 2020. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Shell Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Shell Asset Management sold 1,862 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $281K.
  • Shell Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 17 quarters.
  • Shell Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $396K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Shell Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.